Phathom Pharmaceuticals, Inc. (PHAT) — SEC Financial Statements & Analysis

Phathom Pharmaceuticals, Inc. (PHAT) is a pharmaceutical preparations company, incorporated in DE. Phathom Pharmaceuticals, Inc. trades on Nasdaq as: PHAT. Phathom Pharmaceuticals, Inc. (PHAT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, Phathom Pharmaceuticals, Inc. carries a market cap of $908.66M, a P/E ratio of -9.17x, a P/B ratio of -2.64x, a P/S ratio of 3.79x, an enterprise value of $890.77M, and an EV/EBITDA multiple of -22.20x. On profitability, it posts a gross margin of 82.92%, an operating margin of -16.96%, a net margin of -41.34%, a Return on Equity (ROE) of 26.42%, and a Return on Assets (ROA) of -34.32%. Per share, it reports EPS of $-1.18, diluted EPS of $-1.18, free cash flow per share of $-0.44, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 110.16% year-over-year, net income growth of -69.99% year-over-year, and EPS growth of -74.03% year-over-year. On the balance sheet, it maintains a current ratio of 1.92x, a quick ratio of 1.82x, working capital of $142.14M, a debt-to-equity ratio of -1.95x, a debt ratio of 2.05, an interest coverage ratio of -0.64x, free cash flow of $-36.91M (TTM), and net debt of $-17.89M. Figures sourced from SEC EDGAR.

Market Cap

$908.66M

P/E TTM

-9.17x

EPS TTM

$-1.18

P/B TTM

-2.64x

ROE TTM

26.42%

ROA TTM

-34.32%

Debt To Equity

-1.95x

Free Cash Flow TTM

$-36.91M

Net Revenue TTM Growth 1Y

110.16%

Data as of 2026-06-30 · Source: SEC EDGAR